These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review. Rebello J; Brashier B; Shukla S Daru; 2022 Jun; 30(1):229-243. PubMed ID: 35094370 [TBL] [Abstract][Full Text] [Related]
23. Predicting Exposure After Oral Inhalation of the Selective Glucocorticoid Receptor Modulator, AZD5423, Based on Dose, Deposition Pattern, and Mechanistic Modeling of Pulmonary Disposition. Bäckman P; Tehler U; Olsson B J Aerosol Med Pulm Drug Deliv; 2017 Apr; 30(2):108-117. PubMed ID: 27740878 [TBL] [Abstract][Full Text] [Related]
24. Mathematical model for the selective deposition of inhaled pharmaceuticals. Martonen TB J Pharm Sci; 1993 Dec; 82(12):1191-9. PubMed ID: 8308694 [TBL] [Abstract][Full Text] [Related]
25. Influence of E-Liquid Humectants, Nicotine, and Flavorings on Aerosol Particle Size Distribution and Implications for Modeling Respiratory Deposition. Stefaniak AB; Ranpara AC; Virji MA; LeBouf RF Front Public Health; 2022; 10():782068. PubMed ID: 35372219 [TBL] [Abstract][Full Text] [Related]
26. One (sub-)acinus for all: Fate of inhaled aerosols in heterogeneous pulmonary acinar structures. Hofemeier P; Koshiyama K; Wada S; Sznitman J Eur J Pharm Sci; 2018 Feb; 113():53-63. PubMed ID: 28954217 [TBL] [Abstract][Full Text] [Related]
27. Same lung deposited dose in dog dosing a fine and coarse aerosol indicates no difference in intranasal filtration. Brülls M; Oag S; Karlsson CA; Lamm Bergström E Int J Pharm; 2022 Aug; 624():121977. PubMed ID: 35792234 [TBL] [Abstract][Full Text] [Related]
28. A comprehensive physiologically based pharmacokinetic (PBPK) model for nicotine in humans from using nicotine-containing products with different routes of exposure. Rostami AA; Campbell JL; Pithawalla YB; Pourhashem H; Muhammad-Kah RS; Sarkar MA; Liu J; McKinney WJ; Gentry R; Gogova M Sci Rep; 2022 Jan; 12(1):1091. PubMed ID: 35058535 [TBL] [Abstract][Full Text] [Related]
29. Use of PBPK Modeling To Evaluate the Performance of Dissolv It, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products. Hassoun M; Malmlöf M; Scheibelhofer O; Kumar A; Bansal S; Selg E; Nowenwik M; Gerde P; Radivojev S; Paudel A; Arora S; Forbes B Mol Pharm; 2019 Mar; 16(3):1245-1254. PubMed ID: 30640475 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic profile analyses for inhaled drugs in humans using the lung delivery and disposition model. Raut A; Dhapare S; Venitz J; Sakagami M Biopharm Drug Dispos; 2020 Feb; 41(1-2):32-43. PubMed ID: 31691979 [TBL] [Abstract][Full Text] [Related]
31. Use of quantitative Moreau M; Simms L; Andersen ME; Trelles Sticken E; Wieczorek R; Pour SJ; Chapman F; Roewer K; Otte S; Fisher J; Stevenson M Front Toxicol; 2024; 6():1373325. PubMed ID: 38665213 [TBL] [Abstract][Full Text] [Related]
33. Multicomponent aerosol particle deposition in a realistic cast of the human upper respiratory tract. Nordlund M; Belka M; Kuczaj AK; Lizal F; Jedelsky J; Elcner J; Jicha M; Sauser Y; Le Bouhellec S; Cosandey S; Majeed S; Vuillaume G; Peitsch MC; Hoeng J Inhal Toxicol; 2017 Feb; 29(3):113-125. PubMed ID: 28470142 [TBL] [Abstract][Full Text] [Related]
34. Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling. Yamazaki H; Horiuchi K; Takano R; Nagano T; Shimizu M; Kitajima M; Murayama N; Shono F Int J Environ Res Public Health; 2010 Sep; 7(9):3406-21. PubMed ID: 20948932 [TBL] [Abstract][Full Text] [Related]
36. Influences of puff protocols and upper airway anatomy on cannabis pharmacokinetics: A CFPD-PK study. Zhao J; Feng Y; Tian G; Taylor C; Arden NS Comput Biol Med; 2021 May; 132():104333. PubMed ID: 33770654 [TBL] [Abstract][Full Text] [Related]
37. Pulmonary and Regional Deposition of Nebulized and Dry Powder Aerosols in Ferrets. Kuehl PJ; Chand R; McDonald JD; Hava DL; DeHaan WH AAPS PharmSciTech; 2019 Jul; 20(6):242. PubMed ID: 31264190 [TBL] [Abstract][Full Text] [Related]
38. A Partial Differential Equation Approach to Inhalation Physiologically Based Pharmacokinetic Modeling. Boger E; Wigström O CPT Pharmacometrics Syst Pharmacol; 2018 Oct; 7(10):638-646. PubMed ID: 30084547 [TBL] [Abstract][Full Text] [Related]
39. In vitro, ex vivo and in vivo methods of lung absorption for inhaled drugs. Sakagami M Adv Drug Deliv Rev; 2020; 161-162():63-74. PubMed ID: 32763274 [TBL] [Abstract][Full Text] [Related]
40. The impact of pulmonary diseases on the fate of inhaled medicines--a review. Wang YB; Watts AB; Peters JI; Williams RO Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]